Spyros Maragkoudakis

Spyros Maragkoudakis

Auto-generated profile, based on publicly available information

Spyros Maragkoudakis

Department of Cardiology Chania General Hospital ‘Agios Georgios’ Chania Greece

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
SMSpyros Maragkoudakis
Spyros Maragkoudakis
IAIoannis Anastasiou
Ioannis Anastasiou
HNHelen Nakou
Helen Nakou
MPMarina Plataki
Marina Plataki
FPFragiskos I. Parthenakis
Fragiskos I. Parthenakis
Salt has been linked very closely to the occurrence and complications of arterial hypertension. A large percentage of patients with essential hypertension are salt‐sensitive; that is, their blood pressure increases with increased salt intake and decreases with its reduction. For this reason, emphasis is placed on reducing salt intake to better regulate blood pressure. In day‐to‐day clinical practice this is viewed as mandatory for hypertensive patients who are judged to be salt‐sensitive. Previous studies have highlighted the negative effect of high‐salt diets on macrovascular function, which also affects blood pressure levels by increasing peripheral resistances. More recent studies provide a better overview of the pathophysiology of microvascular disorders and show that they are largely due to the overconsumption of salt. Microvascular lesions, which have a major impact on the functioning of vital organs, are often not well recognized in clinical practice and are not paid sufficient attention. In general, the damage caused by hypertension to the microvascular network is likely to be overlooked, while reversion of the damage is only rarely considered as a therapeutic target by the treating physician. The purpose of this review is to summarize the impact and the harmful consequences of increased salt consumption in the microvascular network, their significance and pathophysiology, and at the same time to place some emphasis on their treatment and reversion, mainly through diet.

8 July 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
SMSpyros Maragkoudakis
Spyros Maragkoudakis
KFKostantinos Fragiadakis
Kostantinos Fragiadakis
JKJohn Konstantinou
John Konstantinou
APAlexandros PAtrianakos
Alexandros PAtrianakos
FPFragiskos I. Parthenakis
Fragiskos I. Parthenakis
Heart failure (HF) with mid‐range ejection fraction (HFmrEF) is a newly suggested entity in HF. Since it has been inadequately addressed, there is an urgent need to determine the profile of HFmrEF patients and the optimal approach to their management. The present study aimed to assess the long‐term clinical outcomes of hypertensive patients with HFmrEF and the impact of blood pressure (BP) on their mortality and cardiovascular outcome. We performed a retrospective observational study that included 121 hypertensive patients with HFmrEF and 149 hypertensives with heart failure and preserved ejection fraction (HFpEF). The median follow‐up was 84 months (22‐122). Our analysis did not reveal any statistically significant difference between the two groups in total mortality (P = 0.34) or cardiovascular mortality (P = 0.54). The total mean survival time was 102.9 months (100.5‐110.1), while the mean survival time was 105.3 months (80.4‐90.2) in HFpEF and 97.6 months (92.7‐102.6) in HFmrEF. An office systolic BP > 139 mm Hg and diastolic BP > 89 mm Hg were significantly associated with both all‐cause mortality (P = 0.02 and P = 0.013, respectively) and cardiovascular mortality (P = 0.02 for both). In HFpEF patients, no significant association was found between outcome and office BP. HFpEF and HFmrEF have similar long‐term outcomes. Suboptimal BP levels are a significant risk factor for an adverse outcome in HFmrEF. Our results emphasize the importance of good BP control in order to achieve better outcomes in hypertensives with impaired EF and HF symptomatology.

6 September 2026 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
VPVictoria Potoupni
Victoria Potoupni
ABAristi Boulmpou
Aristi Boulmpou
SMSpyridon Maragkoudakis
Spyridon Maragkoudakis
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
EFEMMANOUIL FOUKARAKIS
EMMANOUIL FOUKARAKIS
CPChristodoulos Papadopoulos
Christodoulos Papadopoulos
Introduction: Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium–glucose cotransporter‐2 (SGLT2) inhibitors have emerged as a cornerstone therapy for HFrEF, significantly reducing hospitalizations and mortality regardless of glycemic status, sex, race, or comorbidities. Methods: EVOLUTION‐HF was an observational, multi‐center, longitudinal cohort study involving 257 consecutive patients diagnosed with HFrEF who initiated dapagliflozin in a routine clinical setting in Greece. The primary objectives were to characterize baseline demographic and clinical features of patients newly initiated on dapagliflozin for HFrEF and to evaluate dapagliflozin treatment patterns, including discontinuation timing, reasons for discontinuation, and concomitant heart failure and glucose‐lowering therapies over time. The secondary objectives are to describe patient‐reported outcomes using the KCCQ‐23 and to assess adherence to dapagliflozin among patients with HFrEF. Results: A total of 257 patients were enrolled and the follow‐up period lasted for 12 months. Significant improvements among all KCCQ‐23 scores were observed from baseline to 12‐months post dapagliflozin initiation, revealing that the initiation and optimization of guideline‐directed medical therapy in routine clinical practice provides improvement to quality of life over time. Conclusions: Dapagliflozin was safe and well‐tolerated throughout the observation period. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow‐up in these higher‐risk groups.